flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

reMYND raises 12 million EUR to assess clinical proof-ofmechanism in Alzheimer’s and to expand into orphan disorders

reMYND NV announced today the closing of a 12 million EUR financing round to

  • Advance its Alzheimer program into clinical testing and assess its novel mechanism in patients;
  • Broaden the pipeline into CNS orphan programs, including Huntington and ALS;
  • Further innovate and expand the service offering of its CRO; and
  • Strengthen the executive team and board.

 

Finance | 18 December 18 Read more

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Galapagos NV (Euronext & NASDAQ: GLPG) today announces that it has dosed its first patient in the worldwide ISABELA Phase 3 program with autotaxin inhibitor GLPG1690 in IPF.

Mithra announces Myring™ update

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that its US commercial partner Mayne Pharma LLC[1] has received a Complete Response Letter from the US Food & Drug Administration (FDA) related to the abbreviated new drug application (ANDA) for Myring™, the vaginal ring made of ethylene vinyl acetate copolymers (EVA).

Patients | 14 December 18 Read more

MyCartis to engage in point-of-need testing with the ANTELOPE Dx platform technology

Today, MyCartis announces the addition of a point-of-need testing technology, ANTELOPE Dx, to complement its immuno-assay technology offering.
MyCartis has developed immunoassay technology, DMAT® [1], which is integrated in its real-time immuno-diagnostic EVALUTION® platform. DMAT® delivers an unmatched combination of features, covering multiplexing, assay speed and analytical performance, together with the unique ability to qualify immune responses directly.

Research | 13 December 18 Read more

flanders.bio events, trainings & international missions

Strategic Partners